Imaxio is a Lyon and Saint-Beauzire, France–based biopharmaceutical company specializing in vaccines and genomics. Its core technology is the IMX313 carrier protein platform, which the company is advancing clinically. Imaxio has filed a marketing authorization application in France for its leptospirosis vaccine and plans to update that application with a view to international commercialization. The company intends to use recent funding to support clinical development of the IMX313 platform and progress regulatory work on the leptospirosis vaccine. Imaxio works with numerous institutional and academic partners, including the Jenner Institute at Oxford, Pierre Fabre, the U.S. Department of Agriculture, the French national influenza research center, Inserm and CNRS research teams. The company has 24 employees, ten of whom are engaged in R&D, and reported turnover of EUR 2.4m in 2011.

Total raised

$4M

Funding rounds

1

Latest round

Equity

Latest activity

Apr 2012